L. Kuti, D. P. Nicolau; Ctr. for Anti-Infect. Res. Dev., Hartford Hosp., Hartford, CT. Jakobsen Firsov Kim

195 WEDNESDAY SCIENTIFIC SESSIONS Final Program A-1962 PharmacokineticPharmacodynamic PKPD Analysis for Efficacy of JNJ-Q2 Using Phase 2 Data from Patients with Acute Bacterial Skin and Skin Structure Infections ABSSSI

S. M. Bhavnani

1 , J. P. Hammel 1 , S. A. Van Wart 1 , M. Melhem 1 , C. M. Rubino 1 , J. M. Davenport 2 , G. F. Mc Intyre 2 , P. G. Ambrose 1 ; 1 ICPD, Latham, NY, 2 Furiex Pharmaceuticals, Morrisville, NC. A-1963 Decrease of Levofloxacin Fecal Concentrations in Experi- mental Dogs Using DAV132, an Oral Adsorbent Delivered to the IleumColon S. Sayah-Jeanne 1 , E. Chachaty 2 , T. Nguyen 3,4 , V. Augustin 1 , J. de Gunz- burg 1 , F. Mentré 3,4 , A. Andremont 5,6 ; 1 Da Volterra, Paris, France, 2 Institut Gustave-Roussy, Villejuif, France, 3 UMR738 INSERM, Paris, France, 4 Univ. Paris Diderot, Paris, France, 5 EA 3964 Univ. Paris Diderot, Paris, France, 6 Hosp. Bichat, AP-HP, Paris, France. A-1964 Levofloxacin LVX Penetration into Epithelial Lining Fluid ELF Differs Between Infected and Uninfected Patients

J. L. Kuti, D. P. Nicolau; Ctr. for Anti-Infect. Res. Dev., Hartford Hosp., Hartford, CT.

A-1965 Ciprofloxacin CIP PKPD in Experimental Urinary Tract Infection UTI Depends on TimeMIC and not AUC24MIC

L. Jakobsen

1,2 , K. S. Jensen 1 , C. Vingsbo Lundberg 1 , N. Frimodt- Møller 1,2,3 ; 1 Statens Serum Inst., Copenhagen, Denmark, 2 Hvidovre Hosp., Hvidovre, Denmark, 3 Hvidovre Univ. Hosp., Hvidovre, Denmark. A-1966 External Evaluation of a Mechanism-Based PKPD Model: Predicting In Vitro Resistance Selection in Competition Experiments D. Khan, P. Lagerbäck, E. Gullberg, S. Cao, C. Malmberg, O. Cars, D. Hughes, D. I. Andersson, E. I. Nielsen, L. E. Friberg; Uppsala Univ., Uppsala, Sweden. A-1967 Testing the Mutant Selection Window Hypothesis with Fluoroquinolone-Exposed Escherichia coli in an in Vitro Dynamic Model: Examination of Alternative Predictors of Resistance A. A. Firsov 1 , E. N. Strukova 1 , D. S. Shlykova 1 , Y. A. Portnoy 1 , S. A. Dovzhenko 1 , M. B. Kobrin 1 , S. H. Zinner 2 ; 1 Gause Inst. of New Antibiotics, Moscow, Russian Federation, 2 Mount Auburn Hosp., Cambridge, MA. A-1968 Pharmaceutical Equivalence PE, Therapeutic Equivalence TE, and Resistance R Selection of 5 Generic Products of Ciprofloxacin CIP Compared with the Innovator against Pseudomonas aeruginosa C. A. Rodriguez, M. Agudelo, J. A. Perez, J. M. Gonzalez, O. Vesga; Univ. of Antioquia, Medellin, Colombia. ------------------------------------------------------------------------ 242 C1 Poster Session Mechanisms of Resistance to Novel Compounds Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: C1-1969 Structure of Plusbacin Bound to Bacterial Cell Walls

S. Kim

1 , R. D. O’Connor 2 , M. Singh 2 , C. Cao 3 , M. VanNiewenhze 3 , J. Schaefer 2 ; 1 Baylor Univ., Waco, TX, 2 Washington Univ., St. Louis, MO, 3 Indiana Univ., Bloomington, IN. C1-1970 Dynamics and Mechanisms of Resistance Development to Ceftazidime, Meropenem and CeftolozaneTazobactam in Wild- Type and Mutator P.aeruginosa Strains G. Cabot, X. Mulet, B. Moyà, L. Zamorano., C. Juan, A. Oliver; Hosp. Son Espases, Palma de Mallorca, Spain. C1-1971 Single- and Multistep Resistance Selection with the Pleuro- mutilin Antibiotic BC-3781

S. Paukner